Intraputaminal Delivery of Adeno‐Associated Virus Serotype 2<b>–</b>Glial Cell Line–Derived Neurotrophic Factor in Mild or Moderate Parkinson's Disease
Bilateral intraputaminal AAV2-GDNF gene therapy was well tolerated and associated with numerical stability (mild cohort) and improvement (moderate cohort) in clinical assessments at 18 months posttreatment. © 2025 AskBio Inc and The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Authors
- Adrian P. Kells
- Aristide Merola (ORCID: https://orcid.org/0000-0002-5587-726X)
- Chadwick W. Christine (ORCID: https://orcid.org/0000-0003-4166-9432)
- Nicolás Phielipp (ORCID: https://orcid.org/0000-0002-4631-7551)
- Michael Wisniewski (ORCID: https://orcid.org/0000-0002-7481-5590)
- Krystof S. Bankiewicz (ORCID: https://orcid.org/0000-0002-0424-3566)
- Massimo S. Fiandaca (ORCID: https://orcid.org/0000-0002-8376-1934)
- Amber D. Van Laar (ORCID: https://orcid.org/0000-0002-8912-3159)
- J. Bradley Elder (ORCID: https://orcid.org/0000-0002-6650-3271)
- Waldy San Sebastián (ORCID: https://orcid.org/0000-0002-2776-7944)
- Paul Larson
Institutions
- University of Arizona (US)
- University of California, San Francisco (US)
- University of California, Irvine (US)
- The Ohio State University Wexner Medical Center (US)
- AskBio (United States) (US)
- Neurological Surgery (US)
Publication Details
- Journal
- Movement Disorders
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1002/mds.30193
- Citations
- 16
- Primary Topic
- Nerve injury and regeneration
- Type
- article
- Field-Weighted Citation Impact
- 14.55
Funders
- California Institute for Regenerative Medicine
- Neurocrine Biosciences